Radiopharmaceuticals Market Size is Anticipated to reach USD 38.6 Billion by 2040

According to a recently published report, the continuous innovation in radioisotope production and need for highly targeted and effective radiopharmaceuticals has positioned the market as a transformative modality in precision diagnostics and therapy

Radiopharmaceuticals Market Overview

The radiopharmaceuticals market is expected to reach USD 38.6 billion by 2040, representing a CAGR of 8.0%, during the forecast period.

Radiopharmaceuticals are engineered to deliver radioactive isotopes with high precision to specific biological targets, enabling more accurate diagnosis and targeted treatment while minimizing unnecessary exposure to healthy tissue. The market is supported by advancements in isotope production, targeting vectors, radiochemistry, and theranostic applications. Additionally, the demand for radiopharmaceuticals continue to rise as personalized medicine gains momentum, nuclear medicine expands in precision oncology and other therapeutic areas, and healthcare providers seek more precise and effective treatment options.

Browse ~150 figures and ~160 market data tables spread across 270+ slides and detailed Table of Content on “Radiopharmaceuticals Market (2nd Edition), till 2040 by Type of Radioisotope (Technetium-99m, Leutetium-177, Fluorine-18 and Others), Type of Emitter (Gamma Emitters, Beta Emitters and Others), Purpose of Radiopharmaceutical (Therapeutic Radiopharmaceuticals and Diagnostic Radiopharmaceuticals), Type of Diagnostic Radiopharmaceutical (PET Imaging Agents and SPECT Imaging Agents), Type of Production Method (Nuclear Reactors, Accelerators / Cyclotrons and Others), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders,  Hormonal Disorders, Gastrointestinal Disorders and Others), End-user (Hospitals, Diagnostic Centers and Research Institutes) and Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) here: https://www.rootsanalysis.com/reports/radiopharmaceuticals-market.html

Market Drivers

Several key factors are propelling the growth of the radiopharmaceuticals market. Among these, the rising global burden of chronic diseases such as cancer is a key driver that is significantly increasing the demand for radiopharmaceuticals. Further, technological innovations, including advanced radionuclide imaging systems (such as PET), and AI integrated processes, coupled with launch of novel radioligand therapies (such as alpha therapies) are significantly enhancing the precision and efficacy of radiopharmaceuticals. In addition, the radiopharmaceutical sector is witnessing increased funding activity and increased support from governments which is driving the growth of this market.

Market Restraints

Despite strong growth potential, the radiopharmaceuticals market faces several restraints that may limit expansion. A primary challenge is the complex manufacturing and handling process, which requires specialized facilities, strict radiation safety controls, and efficient isotope supply chains. Regulatory complexity, short half-lives of certain isotopes, and transportation constraints also create operational hurdles. Furthermore, high development costs, limited reimbursement in some markets, and concerns related to radiation exposure can slow broader adoption. 

Growth Factors

Even with these restraints, several growth factors are accelerating the radiopharmaceuticals market. A key factor is the expanding clinical use of radioligand therapies and molecular imaging agents across oncology, neurology, and cardiology. The growing pipeline of novel isotopes, improved chelators, and next-generation targeting vectors is enhancing treatment specificity and safety. Further, rising investment from pharmaceutical companies, strategic partnerships, and increasing approvals of radiopharmaceutical products are also driving the market forward.

Radiopharmaceuticals Market Segments 

Based on the type of radioisotopes, the market is segmented into technetium-99m, leutetium-177, fluorine-18 and others

• The radiopharmaceuticals using technetium-99m sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of close to 50%, in the current year.
• The higher share of technetium-99m radioisotopes is because it is the most widely used radioisotope in diagnostic nuclear medicine, with over 10,000 hospitals worldwide relying on it to detect cancer, cardiovascular diseases, and other chronic conditions.

Based on the type of emitter, the market is segmented into gamma emitters, beta emitters and others

• The gamma emitting radiopharmaceuticals sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 65%, in the current year.
• The beta emitting radiopharmaceuticals sub-segment is anticipated to grow at a higher CAGR of 10.4%, during the forecast period.

Based on the purpose of radiopharmaceuticals, the market is segmented into therapeutic radiopharmaceuticals and diagnostic radiopharmaceuticals

• The therapeutic radiopharmaceuticals sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 70%, in the current year.
• The diagnostic radiopharmaceuticals is anticipated to grow at an annualized rate of 7.0% during the forecast period.

Based on the type of diagnostic radiopharmaceutical the market is segmented into PET imaging agents and SPECT imaging agents

• The SPECT imaging agents sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of close to 70%, in the current year.    
• The PET imaging agents sub-segment is anticipated to show the highest growth rate of 9.0% during the forecast period.

Based on the type of production method the market is segmented into nuclear reactors, accelerators / cyclotrons and others

• The nuclear reactors generated radiopharmaceuticals sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 75% in the current year.    
• This can be attributed to the well-established reactor-based production infrastructure, which supports reliable large-scale output of key radioisotopes. Additionally, nuclear reactors can produce substantial quantities of precursor isotopes consistently. Hence, they remain the preferred source for many radiopharmaceuticals, especially those needed in high volumes for clinical use. 

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, neurological disorders, hormonal disorders, gastrointestinal disorders and others

• The oncological disorders sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 40% in the current year.    
• The neurological disorders sub-segment is anticipated to grow at the highest rate (CAGR of 9.0%), during the forecast period.

Based on the end user, the market is segmented into hospitals, diagnostic centers and research institutes

• The hospitals sub-segment led the global radiopharmaceuticals market, capturing the largest revenue share of more than 45% in the current year. Driven by high patient volume, advanced nuclear medicine departments and routine use for diagnosis and therapy    
• The research institutes sub-segment is anticipated to grow at the highest rate (CAGR of 8.9%), during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America

• North America dominated the global radiopharmaceuticals market and accounted for the largest revenue share of close to 45%, in the current year.
• In Asia-Pacific, the global radiopharmaceuticals market is anticipated to demonstrate lucrative growth, with an annualized rate of 9.4% during the forecast period.

Key Companies Profiled

The radiopharmaceuticals market report also includes detailed profiles of key companies (listed below) that are engaged in the radiopharmaceuticals domain:

• 3BP Pharmaceuticals
• Curium
• ITM Radiopharma
• Jubilant Radiopharma
• Lanthues
• Yantai LNC Biotechnology 
• Norroy Biosciences
• Sinotau Pharmaceutical
• Telix Pharmaceuticals 

You Can Download Free Sample PDF Copy of This Report At: https://www.rootsanalysis.com/reports/radiopharmaceuticals-market/request-sample.html

About Roots Analysis

Roots Analysis is a global life sciences market research, competitive intelligence, and strategic consulting firm specializing in the pharmaceutical, biotechnology, medical devices and healthcare industries. Founded in 2013, we have served 1,500+ global clients, from startups to Fortune 500 companies, helping them evaluate market opportunities, assess competition, and make data-driven business decisions. We also provide dedicated solutions to academic institutes, universities, non-profit organizations and other non-industry players.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com